Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have
recently been introduced and may have advantages over vitamin K antagonists such as …

Protein C (PC) deficiency is a heritable or acquired risk factor for thrombophilia, with
presentations varying from asymptomatic to venous thromboembolism to neonatal purpura …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

The direct oral anticoagulants (DOACs), now including dabigatran, apixaban and
rivaroxaban, have given clinicians alternative options to low molecular weight heparins …

The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a
direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa …

Hypercoagulability can result from a variety of inherited and, more commonly, acquired
conditions. Testing for the underlying cause of thrombosis in a patient is complicated both by …

Non-vitamin K antagonist oral anticoagulants (NOAC), including rivaroxaban, apixaban or
dabigatran, regularly show relevant effects on coagulation tests, making the interpretation of …

Antiphospholipid syndrome (APS) encompasses a wide spectrum of disease manifestations
that may prevail in the form of venous or arterial thrombosis or lead to pregnancy …

To accurately estimate longitudinal changes in individuals, it is important to take into
consideration the biological variability of the measurement. The few studies available on the …

Direct oral anticoagulants (DOACs) or non-vitamin K oral anticoagulants (NOACs) are
increasingly used in the prevention of recurrent venous thromboembolism (VTE), including …